Navigation Links
When nerve meets muscle, biglycan seals the deal
Date:2/14/2012

PROVIDENCE, R.I. [Brown University] A protein that has shown early promise in preventing the loss of muscle function in mouse models of Duchenne muscular dystrophy, has been found in a new study to be a key player in the process of joining nerves to muscles.

The protein biglycan needs to be present to stabilize synapses at the neuromuscular junction after they have formed, according to research led by Brown University that appears in the Feb. 14, 2012, issue of the Journal of Neruoscience.

"What neuromuscular junctions do second-by-second is essential for our brain to control movement and they are also important for the long-term health of both muscle and motor neurons," said Justin Fallon, profesor of neuroscience at Brown University and the paper's senior author. "A treatment that sustains or supports the synapse could promote the health of motor neurons and muscle."

In previous work, Fallon, a member of the Brown Institute for Brain Science, has shown that in mice with the same genetic mutation as Duchenne patients, biglycan promotes the activity of another natural protein, utrophin, that can significantly reduce the muscle degradation that patients suffer. Utrophin essentially takes over for dystrophin, which is the protein Duchenne patients cannot produce. In 2010 Brown licensed Fallon's biglycan intellectual property to the Providence startup company Tivorsan Pharmaceuticals, which is working toward human trials of biglycan.

Last month the Muscular Dystrophy Association, which helped support Fallon's new study, gave Tivorsan a $1 million grant.

Now Fallon's research group has found another important role for biglycan. In the new multi-institutional study, lead author Alison Amenta and a team of other scientists found that biglycan binds and helps activate and target a receptor enzyme called MuSK, which works like a foreman or master regulator over other proteins that build and stabilize the neuromus
'/>"/>

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
2. OSU chemist developing solution to nerve agent exposure
3. Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas
4. Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas
5. Biosynthetic corneas formulated with recombinant collagen restore vision and nerve growth
6. New insight in nerve cell communication
7. UCF teams advanced nerve cell system could help cure diabetic neuropathy, related diseases
8. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. AllograftPossibilities.org Meets Unmet Need for Consumer-Oriented Information on Tissue Donation, Transplantation on the Internet
11. President Obama Meets U.S. Laureates of 2010 Kavli Prizes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
When nerve meets muscle, biglycan seals the deal
(Date:7/28/2015)... , July 29, 2015 ... acquiring, rapidly developing and commercialising innovative ... health   Highly experienced management team; blue ...   Mereo BioPharma Group Ltd ("Mereo"), ... raised $119m ( c. £76.5m), gross, from blue chip ...
(Date:7/28/2015)... VILLAGE, Nev. , July 28, 2015  PDL ... ) today announced that the Company will release its ... June 30, 2015, on Wednesday, August 5, 2015, after ... and webcast that day at 4:30 p.m. Eastern Time ... to the call will be available via the webcast ...
(Date:7/28/2015)... ... July 28, 2015 , ... In terms ... in 2013; while production volume reached close to 1.84 million tonnes in the ... share of 75.5% of the region’s total aluminium hydroxide production; the country’s aluminium ...
(Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be offering weekly private guided ... local area veterinarians. , The tour and course will be given every Wednesday at ... VetStem’s Poway facility. Staff members are welcome to attend with their veterinarian as well. ...
Breaking Biology Technology:Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2
... , SUNRISE, Fla., Dec. 21 , ... treatment "ASCs Treatment": , A large quantity of stem ... pain and other side effects, quickly and cheaply. Adipose stem ... the healing of damaged blood vessels. Lower limb ischemia is ...
... France, Dec. 21 Ipsogen SA (Alternext: ALIPS) today ... of tumor grade in chemotherapy prescription has been presented ... (SABCS), December 9-13, 2009. , The study was ... France. Using the centre database and a classification tree ...
... Calif., Dec. 21 Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) today ... with Oxford Finance Corporation ("Oxford") for a $3 million term loan. ... 13% per annum and be payable over three years. Under ... facility fee of $60,000 and a final payment fee of $180,000. ...
Cached Biology Technology:Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 2Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 3Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 4Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue 5Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium 2Titan Pharmaceuticals to Receive $3 Million Loan 2Titan Pharmaceuticals to Receive $3 Million Loan 3
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... a man,s guilt through mind reading? What if reading a ... ,intent, to commit murder? These are just some of the ... Cognitive Science, the latest interdisciplinary project from Wiley-Blackwell, which for ... In the article "Neurolaw," in the inaugural issue ...
... in Parkinson,s disease have new evidence that these systems become ... parts of the network appear to respond in a last ... surprised," said Chris Tang, MD, PhD, a Parkinson,s investigator at ... an author of the study, published this month in the ...
... Researchers can predict your performance on a video game ... brain, a multi-institutional team reports this week. The new ... nearly a quarter of the variability in achievement seen among ... be predicted by measuring the volume of three structures in ...
Cached Biology News:Mind reading, brain fingerprinting and the law 2Brain abnormalities in Parkinson's patients develop before symptoms occur 2Video gamers: Size of brain structures predicts success 2Video gamers: Size of brain structures predicts success 3
... High perfomance data acquisition interface. All the ... faster on-board processor, increased memory and more ... The Power1401 also inlcudes an option for ... the standard 16 to 48 waveform inputs ...
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
... System consists of FAST RED chromogen,tablets and ... presence of alkaline phosphatase to produce red ... FAST RED System provides enough material for ... , Vial A: 6 Tablets , Vial ...
Biology Products: